» Articles » PMID: 20179952

Does Pharmacological Dose of Parenteral Arginine Have Beneficial Effect in Rats with Sub-acute Peritonitis?

Overview
Date 2010 Feb 25
PMID 20179952
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: Peritonitis is a life-threatening condition that may occur as a sequela of intra-abdominal infection. The management of peritonitis includes surgical intervention, antimicrobial therapy, and nutritional support. Arginine has been reported to have beneficial and adverse effects in subjects with inflammation, which might be related to the dose, time, and route of supplementation and the disease severity. So far, the optimal doses of parenteral arginine are not known. In this study, we investigated dose effects of parenterally supplemented arginine on anabolism and arginine-derived metabolites in sub-acute inflammation.

Methods And Materials: Male Wistar rats underwent modified cecal puncture procedure for induction of peritonitis were infused with total parenteral nutrition solutions for 7 days, which contained conventional, low, medium, and high doses of arginine, i.e., 1.61, 2.85, 4.08, and 6.54% of calories from arginine. Healthy, orally fed rats were included as references.

Results: On day 7, peritonitic rats had significantly decreased body weight, declined serum albumin, and increased serum nitric oxide (NO) and tumor-necrosis factor-alpha compared to references (ANOVA, P < 0.05). There were no dose effects of parenteral arginine on body weight, nitrogen retention, and serum blood urea nitrogen and creatinine in peritonitic rats. In contrast, plasma arginine, proline, and ornithine, and urinary urea nitrogen were significantly increased, whereas serum NO and plasma glutamine were significantly decreased in dose-dependent manners with parenteral arginine. Pharmacological dose of parenteral arginine may increase the synthesis of ornithine, urea, and proline instead of citrulline and NO in peritonitic rats.

Conclusion: These results suggest that high dose of parenteral arginine may facilitate ureagenesis and proline conversion without causing augmentation of NO production in sub-acute inflammation. Therefore, pharmacological dose of parenteral arginine may not have benefits in anabolism but does not cause adverse effect in rats with sub-acute inflammation.

Citing Articles

The Nitric Oxide Synthase Inhibitor NG-Nitro-L-Arginine Methyl Ester Diminishes the Immunomodulatory Effects of Parental Arginine in Rats with Subacute Peritonitis.

Lo H, Hung C, Huang F, Su T, Lee C PLoS One. 2016; 11(3):e0151973.

PMID: 27007815 PMC: 4805291. DOI: 10.1371/journal.pone.0151973.


The dose-dependent immunoregulatory effects of the nitric oxide synthase inhibitor N(G)-nitro-L-arginine methyl ester in rats with sub-acute peritonitis.

Hsiao C, Lee C, Tsao L, Lo H PLoS One. 2012; 7(8):e42467.

PMID: 22879994 PMC: 3411778. DOI: 10.1371/journal.pone.0042467.

References
1.
Kalil A, Danner R . L-Arginine supplementation in sepsis: beneficial or harmful?. Curr Opin Crit Care. 2006; 12(4):303-8. DOI: 10.1097/01.ccx.0000235206.92697.bf. View

2.
Wang Y, Shang H, Lai Y, Yeh S . Arginine supplementation enhances peritoneal macrophage phagocytic activity in rats with gut-derived sepsis. JPEN J Parenter Enteral Nutr. 2003; 27(4):235-40. DOI: 10.1177/0148607103027004235. View

3.
Gardiner K, Gardiner R, Barbul A . Reduced intestinal absorption of arginine during sepsis. Crit Care Med. 1995; 23(7):1227-32. DOI: 10.1097/00003246-199507000-00012. View

4.
Flynn N, Meininger C, Haynes T, Wu G . The metabolic basis of arginine nutrition and pharmacotherapy. Biomed Pharmacother. 2002; 56(9):427-38. DOI: 10.1016/s0753-3322(02)00273-1. View

5.
Struyf S, Noppen S, Loos T, Mortier A, Gouwy M, Verbeke H . Citrullination of CXCL12 differentially reduces CXCR4 and CXCR7 binding with loss of inflammatory and anti-HIV-1 activity via CXCR4. J Immunol. 2008; 182(1):666-74. DOI: 10.4049/jimmunol.182.1.666. View